TD Cowen analyst Boris Peaker initiated coverage of Vaxcyte with an Outperform rating and no price target. Vaxcyte is developing a 24-valent pneumococcal conjugate vaccine VAX-24 in adults and infants, which has the potential to become a market leading PCV, addressing a $10B total addressable market, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PCVX:
- Vaxcyte Announces Pricing of $500 Million Public Offering
- Vaxcyte price target raised to $68 from $63 at BofA
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte announces offering of common stock, warrants
- New Vaccine Data Sends Vaxcyte Stock Blasting Up